 Half of participants will receive epacadostatpembrolizumabcyclophosphamideCYGVAX pancreas vaccine followed by epacadostatpembrolizumabCRS-207 Arm A, while the other half will receive epacadostatpembrolizumabCRS-207 Arm B. 